Optimizing conventional DMARD therapy for Sjögren's syndrome
Keywords: 6-MP; 6-mercaptopurine; 6-T-GTP; 6-thioguanine triphosphate; ABT; abatacept; Ach; acetylcholine; ALAT; alanine amino transferase; AZA; azathioprine; BAFF; B cell activating factor; Bcl-6; B cell lymphoma 6; bDMARDs; biological disease modifying antirheuma